Dual-targeted molecular imaging of cancer

Emily B. Ehlerding, Lingyi Sun, Xiaoli Lan, Dexing Zeng, Weibo Cai

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Molecular imaging is critical to personalized and precision medicine. Although singly targeted imaging probes are making an impact both clinically and preclinically, molecular imaging strategies using bispecific probes have enabled improved visualization of cancer in recent years through synergistic targeting of two ligands. In this Focus on Molecular Imaging review, we outline how peptide-, antibody-, and nanoparticle-based platforms have affected this emerging strategy, providing examples and pointing out areas in which the greatest clinical impact may be realized.

Original languageEnglish (US)
Pages (from-to)390-395
Number of pages6
JournalJournal of Nuclear Medicine
Volume59
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Molecular Imaging
Precision Medicine
Neoplasms
Nanoparticles
Ligands
Peptides
Antibodies

Keywords

  • Bispecific antibody fragment
  • Cancer
  • Dual-targeted
  • Molecular imaging
  • Positron emission tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Dual-targeted molecular imaging of cancer. / Ehlerding, Emily B.; Sun, Lingyi; Lan, Xiaoli; Zeng, Dexing; Cai, Weibo.

In: Journal of Nuclear Medicine, Vol. 59, No. 3, 01.03.2018, p. 390-395.

Research output: Contribution to journalArticle

Ehlerding, EB, Sun, L, Lan, X, Zeng, D & Cai, W 2018, 'Dual-targeted molecular imaging of cancer', Journal of Nuclear Medicine, vol. 59, no. 3, pp. 390-395. https://doi.org/10.2967/jnumed.117.199877
Ehlerding, Emily B. ; Sun, Lingyi ; Lan, Xiaoli ; Zeng, Dexing ; Cai, Weibo. / Dual-targeted molecular imaging of cancer. In: Journal of Nuclear Medicine. 2018 ; Vol. 59, No. 3. pp. 390-395.
@article{61cba21f403e46a6b277870eb36591ab,
title = "Dual-targeted molecular imaging of cancer",
abstract = "Molecular imaging is critical to personalized and precision medicine. Although singly targeted imaging probes are making an impact both clinically and preclinically, molecular imaging strategies using bispecific probes have enabled improved visualization of cancer in recent years through synergistic targeting of two ligands. In this Focus on Molecular Imaging review, we outline how peptide-, antibody-, and nanoparticle-based platforms have affected this emerging strategy, providing examples and pointing out areas in which the greatest clinical impact may be realized.",
keywords = "Bispecific antibody fragment, Cancer, Dual-targeted, Molecular imaging, Positron emission tomography",
author = "Ehlerding, {Emily B.} and Lingyi Sun and Xiaoli Lan and Dexing Zeng and Weibo Cai",
year = "2018",
month = "3",
day = "1",
doi = "10.2967/jnumed.117.199877",
language = "English (US)",
volume = "59",
pages = "390--395",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - Dual-targeted molecular imaging of cancer

AU - Ehlerding, Emily B.

AU - Sun, Lingyi

AU - Lan, Xiaoli

AU - Zeng, Dexing

AU - Cai, Weibo

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Molecular imaging is critical to personalized and precision medicine. Although singly targeted imaging probes are making an impact both clinically and preclinically, molecular imaging strategies using bispecific probes have enabled improved visualization of cancer in recent years through synergistic targeting of two ligands. In this Focus on Molecular Imaging review, we outline how peptide-, antibody-, and nanoparticle-based platforms have affected this emerging strategy, providing examples and pointing out areas in which the greatest clinical impact may be realized.

AB - Molecular imaging is critical to personalized and precision medicine. Although singly targeted imaging probes are making an impact both clinically and preclinically, molecular imaging strategies using bispecific probes have enabled improved visualization of cancer in recent years through synergistic targeting of two ligands. In this Focus on Molecular Imaging review, we outline how peptide-, antibody-, and nanoparticle-based platforms have affected this emerging strategy, providing examples and pointing out areas in which the greatest clinical impact may be realized.

KW - Bispecific antibody fragment

KW - Cancer

KW - Dual-targeted

KW - Molecular imaging

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85044250384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044250384&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.199877

DO - 10.2967/jnumed.117.199877

M3 - Article

VL - 59

SP - 390

EP - 395

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -